Stock analysts at Jonestrading began coverage on shares of DURECT (NASDAQ:DRRX – Get Rating) in a report released on Tuesday, Benzinga reports. The brokerage set a “buy” rating and a $37.00 price target on the specialty pharmaceutical company’s stock.
DRRX has been the topic of a number of other reports. Cantor Fitzgerald lifted their price objective on DURECT from $37.00 to $44.00 in a research note on Wednesday, March 8th. HC Wainwright lowered their target price on DURECT from $35.00 to $32.00 and set a “buy” rating for the company in a report on Wednesday, March 8th. StockNews.com started coverage on DURECT in a report on Wednesday, January 4th. They issued a “hold” rating for the company. Finally, Oppenheimer lifted their target price on DURECT from $6.00 to $32.00 in a report on Wednesday, December 7th.
DURECT Price Performance
DURECT stock opened at $4.71 on Tuesday. The stock’s 50 day moving average is $5.74 and its 200 day moving average is $5.36. The firm has a market cap of $115.35 million, a P/E ratio of -3.02 and a beta of 1.46. DURECT has a one year low of $3.16 and a one year high of $9.70.
Institutional Trading of DURECT
DURECT Corp. focuses on advancing novel and potentially lifesaving investigational therapies derived from its Epigenetic Regulator Program. Its pipeline is called DUR-928, an endogenous sulfated oxysterol and an epigenetic regulator. The company was founded by James E. Brown and Felix Theeuwes on February 6, 1998 and is headquartered in Cupertino, CA.
- Get a free copy of the StockNews.com research report on DURECT (DRRX)
- Meta Platforms: Efficiency Gains Momentum, Stock Accelerates
- Pfizer’s Latest Acquisition Strengthens the Case for PFE Stock
- SentinelOne: Reversal In-Play For Cybersecurity Stocks
- Is Sportradar Group A Growth Stock To Bet On In 2023?
- Strong Guidance says Boeing is Ready for Takeoff
Receive News & Ratings for DURECT Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DURECT and related companies with MarketBeat.com's FREE daily email newsletter.